Active, not recruitingPhase 2NCT03906292
Frontline Asciminib Combination in Chronic Phase CML
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Jena
- Principal Investigator
- Thomas Ernst, Prof. Dr.University Hospital Jena
- Intervention
- Imatinib(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (21)
- Universitätsklinikum Aachen Medizinische Klinik IV, Aachen, Germany
- Charite Universitätsmeditin Berlin, Campus Virchow Klinikum, Berlin, Germany
- Universitätsklinikum Bonn, Bonn, Germany
- Klinikum Bremen Mitte, Bremen, Germany
- Klinikum Chemnitz gGmbH, Chemnitz, Germany
- GOKOS GmbH, Dresden, Germany
- Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany
- Universitätsklinikum Erlangen, Erlangen, Germany
- Universitätsklinikum Essen, Essen, Germany
- Universitätsklinikum Frankfurt, Frankfurt, Germany
- Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany
- Universitätsklinikum Jena, Jena, Germany
- Universitätsklinikum Leipzig, Leipzig, Germany
- Gemeinschaftspraxis Dres. Müller/ Kröning/ Jentsch-Ullrich/ Tietze/ Krogel, Magdeburg, Germany
- Universitätsmedizin der Johannes- Gutenberg Universität Mainz, Mainz, Germany
- +6 more locations on ClinicalTrials.gov
Collaborators
Ludwig-Maximilians - University of Munich · Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03906292 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics